Alector's low P/S ratio may be due to poor revenue performance and expectations of this trend continuing. Future revenue growth is expected to be significantly lower than the industry, possibly causing discomfort among shareholders and a drop in share price.
Arnon Rosenthal's major sale indicates insiders may expect a lower price. Despite high insider ownership, the absence of insider purchases and significant sales stirs uncertainty about the company's prospects and arouses investor caution.
Mcsnacks H Tupack :
HC wainwright is recalling their loaned out shares is why it's increasing. Then they are going to sell them and send this down to a new low.
Gapping up $ビアサット(VSAT.US)$+5.9% (the Wall Street Journal reported that the satellite company was close to a deal to sell a military communications unit to defense contractor$L3ハリス テクノロジーズ(LHX.US)$for nearly $2 billion.) $Myovant Sciences(MYOV.US)$+31.3% (the biopharmaceutical company rejected a bid by its largest shareholder, Sumitovant Biopharma, to buy the shares it doesn’t already own for $22.75 per share. Myovant said...
63
16
10
報告
RDK79 :
Added on todays 8% (12/5) hopefully over reaction dip on some analyst input…
RDK79 :
Can’t recall which ‘analyst’ but pretty sure there was a recent VSAT downgrade, ie at about 30. Glad I assumed this just another bad employed analyst.
Gainers: •$Antares Pharma(ATRS.US)$+48.7% (to be acquired by Halozyme (HALO) for $5.60 per share) •$Sierra Oncology(SRRA.US)$+37.9% (acquired by GSK for $55 per share) •$Amryt Pharma(AMYT.US)$+11.7% (announces positive long-term safety and efficacy data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL open label extension study in acromegaly patients) •$ブリアセル セラピューティクス(BCTX.US)$+6% (presents development details of...
アレクターに関するコメント
$アレクター(ALEC.US)$
$PacWest Bancorp(PACW.US)$
Who will squeeze best?
All in or just a little?
$ビアサット(VSAT.US)$ +5.9% (the Wall Street Journal reported that the satellite company was close to a deal to sell a military communications unit to defense contractor $L3ハリス テクノロジーズ(LHX.US)$ for nearly $2 billion.)
$Myovant Sciences(MYOV.US)$ +31.3% (the biopharmaceutical company rejected a bid by its largest shareholder, Sumitovant Biopharma, to buy the shares it doesn’t already own for $22.75 per share. Myovant said...
• $Antares Pharma(ATRS.US)$ +48.7% (to be acquired by Halozyme (HALO) for $5.60 per share)
• $Sierra Oncology(SRRA.US)$ +37.9% (acquired by GSK for $55 per share)
• $Amryt Pharma(AMYT.US)$ +11.7% (announces positive long-term safety and efficacy data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL open label extension study in acromegaly patients)
• $ブリアセル セラピューティクス(BCTX.US)$ +6% (presents development details of...
• $ブーズ アレン ハミルトン ホールディング A(BAH.US)$: Goldman Sachs Upgrades to Buy from Neutral - PT $102 (from $83)
• $ヒューマナ(HUM.US)$: UBS Upgrades to Buy from Neutral - PT $520 (from $486)
• $JB ハント トランスポート サービシズ(JBHT.US)$: Deutsche Bank Upgrades to Buy from Hold - PT $230 (from $210)
Downgrades
• $JB ハント トランスポート サービシズ(JBHT.US)$: B.Riley Downgrades to Neutral from Buy - PT $33 (from $62)
• $CACI インターナショナル A(CACI.US)$: Goldman Sachs Downgrad...
まだコメントはありません